1. Home
  2. PK vs IDYA Comparison

PK vs IDYA Comparison

Compare PK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$15.16

Market Cap

3.1B

Sector

Real Estate

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$38.85

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
IDYA
Founded
1946
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.6B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
PK
IDYA
Price
$15.16
$38.85
Analyst Decision
Hold
Strong Buy
Analyst Count
9
16
Target Price
$11.22
$52.86
AVG Volume (30 Days)
3.1M
604.0K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
8.82%
N/A
EPS Growth
N/A
61.90
EPS
0.29
N/A
Revenue
$2,791,000,000.00
$218,710,000.00
Revenue This Year
$2.40
N/A
Revenue Next Year
$2.76
$201.05
P/E Ratio
$51.64
N/A
Revenue Growth
2.35
3024.43
52 Week Low
$9.84
$25.36
52 Week High
$16.20
$42.68

Technical Indicators

Market Signals
Indicator
PK
IDYA
Relative Strength Index (RSI) 47.28 52.15
Support Level $14.28 $35.11
Resistance Level $15.48 $40.58
Average True Range (ATR) 0.40 1.13
MACD -0.07 -0.21
Stochastic Oscillator 41.36 36.51

Price Performance

Historical Comparison
PK
IDYA

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 19,902 rooms across 29 hotels in the United States. Park also has an interest through a joint venture in another 1,424 rooms in another US hotel. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: